Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology - PubMed

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology - PubMed

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Aaron T Gerds 1, Jason Gotlib 2, Prithviraj Bose 3, Michael W Deininger 4, Andrew Dunbar 5, Amro Elshoury 6, Tracy I George 4, Ivana Gojo 7, Krishna Gundabolu 8, Elizabeth Hexner 9, Gabriela Hobbs 10, Tania Jain 7, Catriona Jamieson 11, Andrew T Kuykendall 12, Brandon McMahon 13, Sanjay R Mohan 14, Vivian Oehler 15, Stephen Oh 16, Animesh Pardanani 17, Nikolai Podoltsev 18, Erik Ranheim 19, Lindsay Rein 20, Rachel Salit 15, David S Snyder 21, Brady L Stein 22, Moshe Talpaz 23, Swapna Thota 6, Pankit Vachhani 24, Martha Wadleigh 25, Katherine Walsh 26, Dawn C Ward 27, Mary Anne Bergman 28, Hema Sundar 28

Affiliations 

• PMID: 32886902
 
• DOI: 10.6004/jnccn.2020.0042

Abstract

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

Similar articles

• Myeloid neoplasms with eosinophilia.

  Reiter A, Gotlib J.Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27.PMID: 28028030 Review.
• Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.

  Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C.Ann Hematol. 2013 Jun;92(6):759-69. doi: 10.1007/s00277-013-1695-3. Epub 2013 Feb 12.PMID: 23400675
• A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.

  Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD.Cancer Genet. 2017 Oct;216-217:10-15. doi: 10.1016/j.cancergen.2017.05.001. Epub 2017 May 10.PMID: 29025582
• A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA.

  Zanelli M, Smith M, Zizzo M, Carloni A, Valli R, De Marco L, Foroni M, Palicelli A, Martino G, Ascani S.BMC Pulm Med. 2019 Nov 19;19(1):216. doi: 10.1186/s12890-019-0967-7.PMID: 31744552 Free PMC article.
• World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.

  Shomali W, Gotlib J.Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617.PMID: 31423623 Review.